Pulmonary responses to 5-hydroxytryptamine and endothelin-1 in a rabbit model of left ventricular dysfunction

Cardiovascular Research

Volumn 38, Issue 2, 1998, Pages 500-507

  Deuchar, Graeme A ^a   Hicks, Martin N ^a   Cobbe, Stuart M ^a   Docherty, Cheryl C ^a   Maclean, Margaret R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

5 hydmxytryptamine; Endothelin; Left ventricular dysfunction; Pulmonary Hypertension; Rabbit

Indexed keywords

ENDOTHELIN 1; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOSE RESPONSE; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RABBIT;

ANIMALS; ECHOCARDIOGRAPHY; ENDOTHELIN-1; HYPERTENSION, PULMONARY; MALE; RABBITS; REGRESSION ANALYSIS; SEROTONIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032076598     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00012-1     Document Type: Article

References (34)

1. [1] Costard-Jackle A, Fowler MP. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. JACC 1992;19:48-54.
2. [2] Abramson SV, Burke JF, Kelly JJ, et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Int Med 1992;116:888-895.
3. [3] Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978;58:1107-1122.
4. [4] Trell E. Pulmonary hypertension in disorders of the left heart. Observations in a catheterisation material. Scand J Clin Lab Invest 1973;31:409-418.
5. [5] Paleveski HI, Shloo BL, Pietra GG. Primary pulmonary hypertension. Vascular structure and responsiveness to vasodilator agents. Circulation 1989;80:1207-1221.
6. [6] Rich S, Brundage BB. Pulmonary Hypertension: a cellular basis for understanding the pathophysiology and treatment. JACC 1989;14:545-550.
7. [7] Rabinovitch M, Bothwell T, Hayakawa BN, et al. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. Lab Invest 1986;55:632-653.
8. [8] Dinh-Xuan AJ, Pepke-Zaba J, Butt AY, Cremona G, Higenbottam TW. Impairment of pulmonary artery endothelium-dependent relaxation in chronic lung disease is not due to dysfunction of endothelial cell membrane receptors nor to L-arginine deficiency. Br J Pharmacol 1993;109:587-591.
9. [9] Hunter C, Barer GR, Shaw JW, Clegg EJ. Growth of the heart and lungs in hypoxic rodents: a model of human hypoxic disease. Clin Sci Mol Med 1974;46:375-391.
10. [10] Wanstall JC, O'Donnell SR. Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension. Eur J Pharmacol 1990;176:159-168.
11. [11] Kanai Y, Hori S, Tanaka T, et al. Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc Res 1993;27:1619-1623.
12. [12] Brink C, Cerrina C, Labat C, Verley J, Benveniste J. The effect of contractile agonists on isolated pulmonary arterial and venous muscle preparations derived from patients with primary pulmonary hypertension. Am Rev Respir Dis 1988;37:A106.
13. [13] MacLean MR, Sweeney G, Baird M, et al. 5-hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 1996;119:917-930.
14. [14] Johnson DE, Georgieff MK. Pulmonary neuroendocrine cells. Their secretory products and their potential roles in health and chronic lung disease in infancy. Am Rev Respir Dis 1989;140:1807-1812.
15. [15] Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
16. [16] Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-509.
17. [17] Yoshibayashi M, Nishioka K, Nakao K, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Circulation 1991;84:2280-2285.
18. [18] Yamamoto K, Ikeda U, Mito H, et al. Endothelin production in pulmonary circulation of patients of mitral stenosis. Circulation 1994;89:2093-2098.
19. [19] Sakai S, Miyauchi T, Sakurai T, et al. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. JACC 1996;28:1580-1588.
20. [20] Pye M, Black M, Cobbe SM. Comparison of in vivo and in vitro haemodynamic function in experimental heart failure: use of echocardiography. Cardiovasc Res 1996;31:873-881.
21. [21] Leach E, Howard P, Barer GR. Resolution of hypoxic changes in the heart and pulmonary arterioles during intermittent correction of hypoxia. Clin Sci Mol Med 1977;52:153-162.
22. [22] Denvir MA, MacFarlane NG, Miller DJ, Cobbe SM. Altered calcium handling by the sarcoplasmic reticulum in a coronary ligated model of heart failure in the rabbit. Am J Physiol 1996;271:H850-H859.
23. [23] Enriquez-Sarano M, Rossi A, Seward JB, Bailey KR, Tajik AJ. Determinants of pulmonary hypertension in left ventricular dysfunction. JACC 1997;29:153-159.
24. [24] Herve P, Launay JM, Scrobohaci M-L, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249-254.
25. [25] Ashmore RC, Rodman DM, Sato K, et al. Paradoxical constriction to platelets by arteries from rats with pulmonary hypertension. Am J Physiol 1991;260:H1929-H1934.
26. [26] Schoeffter P, Hoyer D. 5-hydroxytryptamine (5-HT)-induced endothelium-dependent relaxation of pig coronary arteries is mediated by 5-HT receptors similar to the 5-HT1D receptor subtype. J Pharmacol Exp Ther 1990;25:387-394.
27. 7 receptor subtype. Br J Pharmacol 1996;119:1125-1130.
28. [28] Docherty CC, MacLean MR. Effect of nitric oxide synthase inhibition on endothelin responses in small pulmonary arteries from heart failure rabbits. J Hypertens 1996;14:P243. Suppl 1.
29. B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 1996;119:1125-1130.
30. [30] Cowburn PJ, McArthur JD, MacLean MR, et al. Central haemodynamic effects of endothelin-1 in patients with left ventricular dysfunction. JACC 1997;29(2):287A. Suppl A.
31. [31] Douglas SA, Beck GR Jr, Elliot JD, Ohlstein EH. Pharmacologic evidence for the presence of three functional endothelin receptor subtypes in rabbit saphenous vein. J Cardiovasc Pharmacol 1995;26:S163-168. Suppl 3.
32. [32] Wagner OF, Christ G, Wojta J. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-16068.
33. [33] Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. JACC 1994;23:1427-1433.
34. A-Receptor antagonist attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1994;266:H1327-H1331.